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Activation of beta2 adrenoceptors with salbutamol has been reported as cardio toxic. In this study, 
the investigation was to find out whether the beta2 agonist salbutamol protects the myocardium 
from ischemic reperfusion injury, when administered at reperfusion or post reperfusion.  
Administration of beta2 agonist salbutamol (1nM) at the onset of reoxygenation significantly 
decreased the live cells. Moreover, the administration of salbutamol (1nM) in the presence of beta2-
AR selective antagonist ICI 118,551 showed a significant decrease in the live cells through a cardio 
toxic manner. This study further showed that, beta2 agonist salbutamol in the presence of beta1-AR 
selective antagonist CGP 12177 decreased the live cell population. 
Administration of beta2 agonist salbutamol (0.01nM) throughout the reperfusion injury also 
decreased the population of live cells. Also, the administration of salbutamol (0.01nM) with the 
beta2 antagonist ICI and beta1 antagonist CGP showed the decrease in live cells. Besides the 
administration of beta2 agonist salbutamol (1µM, 10nM, and 0.1nM) at the onset of reperfusion 
showed a significant increase in necrosis and the administration of beta2 agonist salbutamol (1nM) 
in the presence of beta2 antagonist ICI throughout the reperfusion injury exposed an increase in the 
necrosis.  
Caspase-3 is an effector caspase. The activity of the Caspase-3 is monitored in this study to detect 
the apoptotic status of cell population. In this study, the intracellular staining of isolated rat 
myocytes with Alexa Fluor® 488 labelled caspase-3 antibodies were used. The flowcytometric 
analysis of caspase-3 activation in cells showed an increase in the caspase-3 level, especially with 
the administration of salbutamol 10nM and 0.1nM. Moreover, the administration of salbutamol 
(1nM, 0.1nM) in the presence and absence of β2 antagonist ICI and the β1 antagonist CGP showed 
a fold increase in the caspase level. 
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Collectively, this study demonstrated that, the administration of β2 agonist salbutamol at the onset 
of reperfusion will not protect the ischemic reperfused rat myocardium from the ischemic 
reperfusion injury. Besides, it causes a toxic effect in the cardiomyocyte with the increase of 
apoptotic and necrotic status of cell population. Also, the decrease in live cells population showed 
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I N T R O D U C T I O N 
 
1. 1 Coronary Artery Disease 
Coronary artery disease is one of the most chronic diseases in the world.  There are many factors in 
the formation of acute myocardial infarction. One of the factors is cardiac ischemia, which is the 
lack of oxygenated blood supply to the heart. There will be some metabolic and structural changes 
in response to myocardial ischaemia. In order to avoid all these complications, reperfusion or 
restoration of myocardial blood flood flow is essential (Colins et al., 1997). 
The various forms of cardiovascular diseases are coronary heart disease (heart attacks), 
cerebrovascular disease, raised blood pressure (hypertension), peripheral artery disease, rheumatic 
heart disease, congenital heart disease and heart failure. Globally, cardiovascular diseases are the 
main cause of death and are projected to remain so. An estimated 17.5 million people died from 
cardiovascular disease in 2005, representing 30 % of all global deaths. In these deaths, 7.6 millions 
were due to heart attacks and 5.7 million due to stroke (Rosamond et al., 2007). Moreover, coronary 
artery disease mainly occurs as a result of dyslipidemia, family history, diabetes and hypertension. 
Studies shows that the obesity rates in the people are also not differ significantly with the coronary 
artery disease (Kolliaki et al., 2010). 
The gradual occurrences of fatty deposits on the walls of coronary arteries are the major cause of 
coronary heart disease. As a result, the coronary artery narrows and makes it harder for the coronary 
artery to supply blood and oxygen. The medical term for this condition is atherosclerosis and the 
fatty material is known as Atheroma. 
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1. 2  Atherosclerosis 
Atherosclerosis is a chronic disease which occurs in the walls of the arteries. This is a very 
progressive disease in which plaques are (consisting of deposits of cholesterol and other lipids, 
calcium, and large inflammatory cells called macrophages) building up in the arteries (Catherine et 
al., 1999). Due to the high impact of these plaques on the arteries will make a partial or complete 
obstruction to the blood flow, which finally creates the sudden occlusion of artery. This condition is 
called as arterial thrombosis. Recent studies showed that high density of lipoproteins can make an 
impact on the risk of atherosclerosis. By multiple pathophysiological mechanisms, these high 
density lipoproteins will reduce the risk of atherosclerosis (Ragbir et al., 2010). 
Figure 1.2.a : The occurrence of plaques in the arteries, which is leading to the ultimate 
blockage of        blood ischemia (NHLBI, Diseases and condition indexes) 
 
This item has been removed due to third party copyright. The unabridged 
version of this thesis can be viewed at the Lanchester library, Coventry 
University. 
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Ischemia is an absolute or relative shortage of the blood supply to an organ. The confliction of 
blood supply (oxygen delivery) and the blood request for adequate oxygenation of the tissue reveals 
the relative shortage. Ischemia of the tissue is due to the lack of oxygen and inability to meet the 
nutrient demand. Ultimately, this causes great damage. As the myocardium is unable to meet 
oxygen demand, the ischemic tissue reverts from aerobic to anaerobic respiration by means of 
generating energy. This process involves the conversion of glucose to lactic acid to yield energy 
leading to significance of lactic acid accumulation in the ischemic zone (Solani and Harris. 2005). 
At the intracellular level, the lingering ischemia has physiological effects like morphological 
changes. (Cell swelling) (Lichtig and Brooks. 1974).Swelling of the cell membrane (sub-lethal 
damage) and the lethal damages (necrosis and apoptosis) are the two ways of occurring cell death 
(Lodish et al., 2004).  During the period of cell swelling, the cells become widened and the 
conductance of the membrane will increase (Tseng et al., 1992). Interference of oxidative 
phosphorylation, adenosine tri-phosphate (ATP) depletion, collapse of the ATP dependant Na+/K+ 
and Ca2+ pumps, decrease in intracellular pH, reversible and irreversible myocyte damage (Graham 
et al., 2004), expansion of the calcium and oxygen paradox (Braunwald and Kloner. 1985) and free 
radical mediated injury also occurred (Wall. 2000).  
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1.3. Cardiac ischemia 
Cardiac ischemia (chest pain) is a pathological condition that is caused by the narrowing of 
significant coronary arteries by pathological processes such as atherosclerotic plaque or blood clot 
formation. In extreme case, complete blockage results in cell death in a few hours and infarction 
(heart attack) progression unless a revascularization procedure is performed as soon as possible. 
The formation of this plagues can originate the narrowing of arteries, where the amount of blood 
flowing is not sufficient to supply oxygen rich blood to the heart, especially during the times of 
physical or emotional stress. There are some physical symptoms like chest pain, pressure or 
discomfort, which is called as Angina. Cardiac ischemia, which occurs for a long period, can be a 
sign of a heart attack. Figure 1.3.a. 
 
 
Figure 1.3.a. The chain of process which is leading to ischemia and finally to death 
(1aim.com) 
This item has been removed due to third party copyright. The unabridged version of this 
thesis can be viewed at the Lanchester library, Coventry University. 




1.4. Myocardial infraction 
 
Myocardial infarction is commonly known as heart attack, which arises due to the atherosclerotic 
plaque. In other words, it is the rapid development of myocardial necrosis caused by a critical 
imbalance between oxygen supply and demand of the myocardium (Nyboe et al., 1989). This 
usually originates from plaque rupture with accumulation of thrombus in a coronary vessel. This 
will result in an acute reduction of blood supply to a portion of the myocardium. The fracturing of 
basement membrane results in the platelet aggregation, thrombus formation, fibrin accumulation, 
hemorrhage into the plaque, and varying degrees of vasospasm ends up in partial or complete 
occlusion of the vessel and ensuing myocardial ischemia (Thygesen et al., 2007). Total occlusion of 
the vessel for more than 4-6 hours results in irreversible myocardial necrosis, but reperfusion within 
this period can restore the myocardium and reduce morbidity and mortality (Lee et al., 2006). 
 
1.5. Pre and Post-Conditioning 
 
 The outcome of studies on reperfusion over the years has shown the importance of implementing 
pharmacological and mechanical interventions at the time of reperfusion. Murry et al., 1986 were 
the first, who shown the significant reduction in infarct size when they introduced the concept of 
ischemic preconditioning (IPC). Prior to this discovery, pharmacological strategies were yielding 
inconsistent results and it was unknown whether anything could be done to protect the ischemic 
heart from cell death.  This powerful endogenous form of cardio protection admits various episodes 
of ischemia which will results in the protection of myocardium from the ischemia. This concludes 
in the arrangement of cardio protective properties like reduction in infarct size, preservation of 
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vascular endothelial function, decrease in polymorpho nuclear neutrophil (PMN) accumulation, and 
reduction in the appearance of apoptosis (Han 2001). The possibility of the cardio protection of this 
strategy has been difficult to relay into clinical practice, because of the inability to predict the onset 
of ischemia.  Recent studies were shown that reperfusion injury can be stopped or reduced by 
adapting the conditions of reperfusion (Judy et al., 1998). 
There are many studies focused on preconditioning which stated a cardio protective effect of 
pharmacological agents. In most of these studies the pharmacological agents are giving before the 
onset of ischemia. But, effectively this procedure is not worth; because it is not possible to detect 
that somebody is going to have a heart attack. Ischemic preconditioning is an experimental 
technique for making the resistance to the blood supply and thereby oxygen to the tissues (Marmor 
et al., 2004).Previous studies proved that the selective pharmacological antagonists like nor-
binaltorphimine di-hydrochloride and GNTI di-hydrochloride of the k-opioid receptors (Kappa 
opioid receptors) are blocking the ischemic preconditioning and the agonists of the same receptors 
mimic the ischemic preconditioning (Gross GJ. 2003). 
There are brief episodes of myocardial ischemia will take place during reperfusion after an 
extended ischemic insult. This may attenuate the total ischemic reperfusion injury. This 
phenomenon has been termed as ischemic post conditioning (Michael et al., 2004). In other words, 
post conditioning is the phenomena in which the reperfusion is interrupted with a vast coronary 
occlusion and reperfusion sequences. It is another form of cardio protection which is similar to the 
pre conditioning (Zaho et al., 2003). The effectiveness of post conditioning has been suggested to 
be as beneficial as preconditioning in limiting infarct size and preserving post ischemic endothelial 
function.  Besides, ischemic post conditioning has a strong anti arrhythmic effect against persistent 
reperfusion induced tachycardia. (Michael et al., 2004) 
Ischemic post conditioning consists of repeated brief cycles of ischemia-reperfusion. This is 
performed immediately after reperfusion followed by a prolonged ischemic insult, which 
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dramatically reduces infarct size in experimental models. Research from the laboratories of Vinten-
Johansen in 1993 have also suggested that, the cardio- protection offered by post conditioning may 
be related to the inhibition of superoxide anion generation and oxidant-mediated cellular membrane 
damage. Recent inventions in the pharmacological sector showed that the post conditioning effect 
can reduce the myocardial infarct size (Staat et al., 1998). 
Previous studies have also observed the significance of relevance of reactive oxygen species (ROS) 
in consider with post conditioning. (Yasuo et al., 2007). These oxygen-derived free radicals 
generate the release of pro-inflammatory mediators, transcription factors and stimulate the surface 
expression of adhesion molecules on the coronary vascular endothelium. The reduction of oxygen 
radicals after post conditioning showed that it may decrease the formation of reactive oxygen 
species (ROS) (Bohuslav et al., 1999).  It is also assumed that, post conditioning may affect the 
release of autacoids (e.g. adenosine and nitric oxide), that may sequentially produce the generation 
of ROS from neutrophils and other cell sources. This is regarded as an important component of the 
cardio protection offered by post conditioning (Rada et al., 2008). 
 
 
1.6. Mechanisms of protection with pre- post-conditioning 
 
Research conducted by Downey and colleagues (1991) were showed the additive effects of 
preconditioning and post conditioning on the same rabbit heart. Ischemic pre conditioning is one of 
the most powerful methods to protect myocardium from the ischemic injury. Before the onset of 
ischemia, there was a protocol of short episodes of myocardial ischemia and reperfusion which will 
protect the myocardium from ischemia and reperfusion (Schluz et al., 2007).Reperfusion is 
essential and an absolute requirement for endurance of the ischemic myocardium. This reperfusion 
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process is able to make some myocardial injuries. The restoration of the circulation causes the 
oxidative damage. When a tissue is subjected to ischemia, a sequence of chemical events is 
initiated, that may ultimately lead to cellular dysfunction and necrosis (Clarke et al., 2005). The 
events of injuries will again take place even after the ischemia which is ended by the reperfusion. 
Thus, the brief decrease or interlude of the blood flow is the result of both ischemic and the 
reperfusion injury. For shorter durations of ischemia, the indirect or reperfusion mediated damage 
becomes more important. For example, it has been shown that the intestinal injury induced by 3 
hours of ischemia (flow reduced to 20% of normal) and one hour of reperfusion is several times 
greater than that observed after 4 hours of ischemia alone (Parks and Granger, 1986).This shows 
that reperfusion plays an important role in ischemia/reperfusion injury. 
 
 
1.7. Cell Death 
Cell death is still a controversial process as it is the triggers that happen during the time of ischemia 
or reperfusion. In order to attain further understanding of reperfusion injury and cardio protective 
strategies, it is also important to gain depth knowledge of cardiac myocyte death. Apoptosis and 
Necrosis are the two different forms of cell death. In necrosis, cell death happens by the bursting of 
cells, and in apoptosis, by the bordering of cells (Freeman et al., 2000). 
 
 
1.8. Apoptosis and necrosis 
 
 Apoptosis is also defined as programmed cell death. A diverse range of cell signals which may 
arise either from extrinsic inducers or intrinsic inducers are the controlling factors of the process of 
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apoptosis (Andrew 2007). Bcl2 proteins are situated in the outer membrane of mitochondria. This 
will involve a major role in defending the cell death. Due to the decrease in intracellular energy and 
the ATP depletion, there will be an absence of apoptosis occurs during ischemia. Therefore, the 
reoxygenation and restoration of glucose supply during reperfusion generates the ATP required for 
the completion of the apoptosis (Popov et al., 2002). Apoptosis and necrosis takes place during the 
early stages of reperfusion (Leist et al., 1997). It is now widely accepted that both necrosis and 
apoptosis are responsible for myocyte cell death during myocardial ischemia and reperfusion.  
Necrosis is characterized as a passive response, which occurs due to the external factors such as 
infections and toxin.  It involves swelling of the cell and its organelles, disruption of mitochondria, 
membrane rupture and cell lysis.  It is a destructive and unregulated process and can subsequently 
cause the death of surrounding cells through the release of its cellular content into the environment.  
In contrast, apoptosis does not cause much damage to surrounding tissue as the cell neatly commits 
suicide in what is often referred to as “programmed cell death”.(Dejean et al., 2006) 
Some studies have confirmed that ischemia itself can trigger apoptosis. (Everett et al., 
1999).Moreover, some studies reveal that, apoptosis has to be co-ordinated by the releasing of 
calcium from the endoplasmic reticulum which synchronizes the mass exodus of cytochrome c 
from mitochondria (Mark et al., 2003). 
The absence of apoptosis during a short period of ischemia is due to the depletion of ATP, which is 
needed for the generation of pro-apoptotic proteins.  Therefore, re- oxygenation and restoration of 
glucose supply during reperfusion generates the ATP required for the completion of apoptosis 
(Santos et al., 2000).  Additional data suggests, apoptosis and necrosis occur simultaneously during 
the early-phase of reperfusion followed by a slower appearance of apoptosis during the later phase 
of reperfusion. However, many controversial theories have arisen with regards to the initiation of 
apoptosis.  Several studies pointed out that, the release or activation of some bioactive substances is 
involved in the triggers in the development of apoptosis. Moreover, some studies proved that, there 
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is a significant co-relation between these triggers and neutrophills on ischemia and reperfusion. And 
this will clearly states the neutrophill activation in the triggering apoptosis (Dejean et al., 2006). 
 
1.9. Caspase 3- Role in the execution phase of cell apoptosis 
 
Caspases, or cysteine-aspartic acid proteases, are the family of cysteine proteases, which plays a 
vital role in apoptosis (programmed cell death). Caspases have variety of roles in apoptosis and in 
the development and most other stages of adult life. So, it is known as the executioner proteins. 
Failure of apoptosis is one of the main contributions to tumour development and autoimmune 
diseases (Harrington et al., 2008). 
 
 Mainly caspase proteins are of two types. One is initiator caspases and the other is effector. 
Initiator caspases (e.g. CASP2, CASP8, CASP9 and CASP10) cleave inactive pro-forms of effector 
caspases. Effector caspases (e.g. CASP3, CASP6, and CASP7) in turn cleave other protein 
substrates within the cell, to trigger the apoptotic process (Gregersen et al., 2007). 
 Apoptosis is a selective process for deletion of cells in various biological systems. In the pathway 
of apoptosis there are various groups of molecules are there. One set of mediators implicated in 
apoptosis are belong to the aspirate-specific cysteinyl proteases. Caspase-3 (CPP32, apopain, 
YAMA) has been identified as a key mediator of apoptosis of mammalian cell (Yuan et al., 2004). 
Kothakota et al, (1997) monitored the paraphrase products of a murine protein library to find the 
substrates that are susceptible to cleavage by caspase-3.  
 
 




1.10. Apoptotic cell signalling pathway 
 
 Extrinsic and Intrinsic are the two apoptotic cell signalling pathways. Extrinsic pathways are also 
called as death receptor pathways. Intrinsic pathways are mediated by mitochondria, which releases 
intermembrane proteins such as cytochrome c, Smac/DIABLO, Endonuclease G, Omi/HtrA2 and 
Apoptosis Inducing Factor (AIF) (Degterev et al., 2008) 
The death receptor pathway (extrinsic) involves the activation of death receptor located on the 
extracellular surface of the cell by apoptotic stimuli. The death receptors are closely related to the 
tumour necrosis factor gene super family and play divergent regulatory roles apart from regulating 
apoptosis (Degterev et al., 2008). Activation of the death receptor will results in the initiation of the 
apoptosis processes this will lead to the receptor association with the adaptor protein Fas associated 
death domain (FADD). FADD has a death effector domain (DED) that associates with pro-capsize 
8. The formation of the FADD-pro-capsize 8 complex results in the immediate cleavage of pro-
capsize 8 to active caspase-8. Activated caspase-8 can bind to pro-caspase-3 resulting in activation 
of caspase-3 and execution of cellular apoptosis.  Caspase-3 results in the cleavage of various death 
substrates and leading to a range of biochemical and morphological changes characters of apoptosis 








Figure 1.10.a.  Proposed mechanism of apoptosis regulation (Gill et al., 2002). 
 
Cell signalling cascades are the primary factor in the apoptotic pathways. Other key regulators of 
apoptosis, which may be used in apoptotic suppressive strategies are stress proteins, growth factors, 
calcium, and oxidants The latest identification of mitochondrial factors (AIF, Endo G and 
Omi/HtrA2) involved in apoptosis has greater importance on unscrambling other mediators of the 
apoptotic program (Salvesen et al.,2008). Almost all of the caspase activations are occurring in 
mitochondria.  The apoptotic death pathway is initiated when the mitochondrial membrane ruptures 
leading to the translocation of cytochrome c and other pro-apoptotic factors into the cytosol.(See 
Figure 1.9.a) Interventions aimed at protecting mitochondrial membrane integrity would  prevent 
the occurrence of downstream morphological changes (Meulmeester et al., 2008). 
The following diagram illustrates the mitochondrial death pathway and the proposed pro-death 
factors that are released from the mitochondrial intermembrane space: 
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Figure 1.10.b. Schematic representation of mitochondrial death decision pores 
(Belizario et al., 2007) 
PT Pores are the large non selective pores which help in the realising of cytochrome c and other 
apoptogenic factors. Proteins of the BCL 2 families may act together with major mitochondrial 
voltage depended anion channel known as VDAC, adenylate nucleotide translocase (ANT) and 
cyclophilin D (Cyclo D). There is also evidence that, the release of apoptogenic factors could occur 
through a putative channel named as mitochondrial apoptosis-inducing channel or MAC (8) and 
through a large channel containing ceramide lipids, i.e., the ceramide channel. 
 
                
 
1.11. Mitochondria and ischemic –reperfusion injury 
 
Mitochondria have a significant role in ischemic-reperfusion injury. Cytochrome c is the heme 
protein in mitochondria, which has been implicated in many studies as an initiator of apoptosis in 
This item has been removed due to third party copyright. The unabridged version of this thesis can be 
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the ischemic reperfused heart (Honda et al., 2005). Cytochrome c will disassociate from 
mitochondria in response to cellular stresses like ROS and calcium overload. The liberation of the 
cytochrome c in to cytoplasm in response to the cell death signals will results in the activation of 
apoptosis. This will occurred by the binding of cytochrome c to Apaf-1 (apoptotic protease 
activating factor 1), which leads to the pattern of apoptosome formation. These apoptosomes will 
binds to ATP and caspase 9 (Lundberg and Szweda. 2004). Caspase 3 can be activated by the 
caspase activation complex which is formatted from these apoptosmes.  
In the transduction of intrinsic apoptotic signal, the Bcl-2 family of proteins plays an important role. 
This is mainly by incorporating the anti apoptotic proteins (Bcl-2 and Bcl-xL) and pro-apoptotic 
proteins (Bax, Bak, Bid, Bad, Bnip3/Nix and others). A major role in regulating apoptotic cell death 
is played by Bcl-2 and Bax proteins. Regulators of apoptosis at the level of caspases have also been 
involved such as cFLIP and the inhibitor of apoptosis (IAP) family, which counteract the effect of 
caspase inhibitors. Decrease in ATP level and   increase in the intracellular ca2+ level are main 
factors in the derangement of mitochondrial function and these alterations will finally cause the 
viability of ischemic myocardium (Fabio et al., 2003). 
 
1.12. Beta Agonists 
Beta agonists are one of the most powerful medications for the bronco related diseases which 
mainly affects on the muscles around the airways. Some studies conducted in the cornel and 
Stanford University’s showed that, common beta agonist inhalers causes’ double death rate in 
COPD patients. There are mainly two types of Beta agonists. One is short acting and other is long 
acting. Beta-agonists can be given in several ways but the most common way is by inhalation. Pills, 
tablets and intravenous forms of the drugs are used but have more side-effects. Some studies 
showed that the effect of beta agonist that stimulates the cardiac contractility and enhance the 
cardiac dysfunction following myocardial ischemia (Yoo et al., 2009) 
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The rapidity in working of short-acting beta-agonists is best when it is compared to the long-acting 
one. Short-acting beta-agonists are the effective medications which gives relief very faster for the 
breathlessness. This breathlessness is often happens due to the frequent showering, exercise, or 
going out in the cold air. The combination of β1, β2 agonists are therapeutically effective in post 
myocardial infarction (Chavasse et al., 2002). 
Unevenness and cramps in the hands are some side effects occurring due to the medication. Also, 
fast heart rate and shakiness causes anxiety (nervousness) and worsens breathlessness. Some of 
these types of illness may occur for a short period of time and after a few days of time it will depart 
by its habitual usage (Spitzer et al., 1992). Occasionally these side-effects may lasts for some period 
of time and have the tendency to continue. Then it should be the time to change the drug. This 
effects are frequently happened due to the over usage of medications which coats the mouth and it 
will get absorbed rather than inhaled (Ramanujan et al., 2006). The representation of the side-
effects is calculated in the frequency in usage of the medications. For instance, various short-acting 
beta-agonists should not be taken more than every 4 hours, except or else instructed by the provider.  
Types of Adrenoceptors 
β1 and β2 adrenoceptors are the two types of adrenoceptors found in the heart. Among these the 
major receptor type in number and function is β1 (Dutta et al., 2002). Sympathetic adrenergic 
nerves are the source of the production of nor-epinephrine in which the β1 receptors are binded very 
firmly. Beta2 agonists must always be used with caution in patients with cardiopathies, since it may 
precipitate the concomitant cardiac disease (Cazzola et al., 2005). Asthma or chronic obstructive 
pulmonary disease (COPD) may occur, when the muscles around the airways may tighten. 
Bronchodilator medicines will relax those muscles by opening the airways. Beta-agonists can be 
administered by inhalers or orally. They activate the beta2 receptor on the muscles surrounding the 
airways. As a result the muscles around the airways relax and may lead to the opening of the 
airways Dilating airways helps to relieve the symptoms of dyspnoea (shortness of breath).It has 
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been shown that the action of β2 agonists to reduce the dyspnoea in many asthma and COPD 
patients. The action of beta2 agonists start within minutes after inhalation and lasts for about 4 
hours. The commencement of action of these β2 agonists is very fast and that will help the patients 
who suffer from shortness of breath symptoms. The duration of action of these are short (Haney and 
Hancox 2007). 
1.13. G-Protein coupled receptors 
 
The pharmaceutical research in the modern world has focused on a various types of protein 
families.  The G-protein coupled receptors (GPCR) are one of the most assorted forms of proteins 
in nature. These are in the variance of the biological and pathological ways like development and 
proliferation, neuromodulation, angiogenesis, metabolic disorders and viral infections 
(Wettschureck et al., 2005). 
G-protein coupled receptors have a critical role as indicators of disease with indicative and 
analytical potential. GPCRs are the principal signal transducers for the sense of sight and smell 
(Ulrik et al., 1998). G-Proteins are the basic source in the activation of adenyl cyclase. These adenyl 
cyclases are meant to be the factor for the formation of cAMP from ATP. cAMP is the major factor 
of the increased amount of calcium entry in the cells. These are mainly by the mechanism of the 
phosphorylation of L-type calcium channels (See Figure 1.12.a.). As a result, this will increase in 
the calcium entry during the action potentials .Also, this may leads to the increase in the 
contractility (King et al., 2003). 
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Figure 1.13.a. shows the ligand binding to a GPCR’s extracellular region triggers 
changes in protein’s trans-membrane region. As a result, the release of guanosine 
diphosphate (GDP) and the uptake of guanosine triphosphate from the G-protein 




Moreover, the activation of these Gs-proteins may leads to the increase in the heart rate, which is by 
the opening of the ion channels which is mainly responsible for the pacemaker current in the 
sinoatrial node. The phosphorylation of protein kinase-A in the sarcoplasmic reticulum causes the 
enhancement of the calcium release through the ryanodine receptors. As a result, supplementary 
doses of calcium will be provided for the binding of the troponin-C.Due to this effect, there will be 
an increase in the inotrpy. At last, the myosin light chains are also be phosphorilated by the PK-A, 
which can also put in to the positive inotropic effect of beta adrenoreceptor stimulation. In 
summary, the cardiac effects of a β-agonist are increased heart rate, contractility, conduction 
velocity, and relaxation rate. Some studies proved that, the inhibition of GRKs to regulate GPCRs 
are useful in the treatment of heart failure and hypertension (Brinks et al., 2010). 
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Salbutamol is one of the most common and very familiar drugs used in the treatment of asthma and 
chronic obstructive pulmonary disease. Asthma is a chronic disease affects on the lungs mainly by 
the inflammation of the lower airways. The airways become sensitive, swollen and inflamed while 
asthma occurs. Salbutamol reduces asthma symptoms by producing the relaxation of airway 
muscles and thus making the breathing easier. In a recent study, the large dose of salbutamol 
increases coronary flow. However, it may have bad effects on patients with coronary artery disease 
(Kochiadakis et al., 2007). 
 
Various forms 
Nebulizers:  These forms deliver the drug straight to the lungs over a long period of time. The 
inhaled forms of salbutamol have a faster onset of action, fewer side effects, and are more effective 
than the syrup or tablet forms. Studies has proved that inhaled or nebulised salbutamol has no effect 
on myocardial ischemia, arrhythmia, and changes in heart rate in patients with CAD and COPD 
(Rossinen et.al., 1998). 
Solution (Injections + syrups): In the case of severe asthma, salbutamol can be injected 
intravenenousily, subcutaneously or intramuscularly 
 
Side effects 
The research studies have proved that the usage of salbutamol in hypoxic patients will cause a 
sudden death (Burggraaf et al., 2001).Most of the side effects include the following: 
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Aggression, agitation, cough, diarrhoea, dizziness, excitement, general bodily discomfort, 
headache, heartburn, increased appetite, increased blood pressure, indigestion, irritability, laboured 
breathing, light-headedness, muscle cramps, nausea, nervousness, nightmares, nosebleed, over 
activity, palpitations, rapid heartbeat, rash, ringing in the ears, shakiness, sleeplessness, stomach 
ache, stuffy nose, throat irritation, tooth discoloration, tremors, vomiting, wheezing, worsening 
bronchospasm (Rossi 2004). 
1.15. Pharmacology of Salbutamol 
Salbutamol is a selective β2 adrenoceptor agonist. Salbutamol will directly precede on the beta2 
adrenoreceptors of the pulmonary bronchial muscles. The bronchodialation happens due to the 
action of salbutamol. Salbutamol stimulates the production of cyclic AMP. This will increases the 
binding of intracellular calcium to the cell membrane and endoplasmic reticulum which leads to the 
bronchodialation. The opening of ATPase channels will coerce the potassium from the extra 
cellular to the intra cellular space. As a result, there will be a decrease in the extra cellular 
hyperkalemia following by the increase in the intracellular potassium (Assoufi et al., 1989). 
The absorption of the salbutamol will takes place in the gastrointestinal tract and the metabolism is 
in the liver. Half of the excretion will occur in the urine and about 30% is excreted as unchanged 
salbutamol. Generally, the action of the bronchodilator will starts within minimum of 3-5 minutes 
and at 15-20 minutes of the maximum (Barnes et al., 1983). 
The possible effect of Salbutamol in Ischemic Heart 
White and his colleges in 2008 have studied the effect of salbutamol in pig’s heart. They concluded 
that, salbutamol is unlikely to increase the severity of cardiovascular diseases (White et al., 2008). 
Others have shown that there are some rare occurrences of myocardial ischemia associated with 
salbutamol (Bennett et al., 1994).  
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However, the pharmaceutical research has given the clear evidences which are more reliable in the 
study of effect of salbutamol in cardiovascular disease. There are some relevant factors which 
showed that salbutamol has an effect of increasing heart rate in cardiac patients. Experiments done 
in 9 patients with the intravenous infusion of salbutamol after cardiac surgical operations resulted 
with a greater increase in the heart rate, maximum acceleration of aortic blood flow, and maximum 
rate of change of left ventricular power (Leitch et al., 1976). But the mean falls in left atrial pressure 
and systemic vascular resistance were similar. These results showed that the variation would 
include more myocardial oxygen consumption with salbutamol. So, the combination of the 
salbutamol has to be controlled very hardly to demonstrate the presence of functional cardiac beta 
2-adrenoceptors. Some studies showed that the salbutamol is a useful drug in heart failure 
(Bourdillon et al., 1980). 
1.15. Aim and Objective 
The aim of this study was to investigate the effect of beta agonist salbutamol in the heart following 
ischemic-reperfusion injury. The aim was to determine whether salbutamol increase the apoptosis, 
necrosis in cardiomyocytes subjected to Hypoxia/Reoxygenation injury. The objective of this study 
was to determine whether the administration of salbutamol in heart during ischemic reperfusion 
injury can cause an increase in  infract size and whether it elicit the necrotic/apoptotic properties in 
isolated myocytes following Hypoxia/Reoxygenation injury. Moreover this study aims to find out 
the effect of beta-2 agonist (salbutamol) in the presence of inhibitors when administered throughout 
the reperfusion injury 




2.1 Langendorff heart perfusion studies 
2.1.1 Introduction to Langendorff heart perfusion studies 
Langendroff preparation is the traditional method in the perfusion of a heart. The normal 
functioning of the heart has to be maintained while the perfusion through the aorta and circulates 
through the coronary artery. 
 
2.1.2. Animal use - Langendorff  
The Male Sprague-Dawley rats (250 g + 50 g body weight) were used in the experiments given by 
Coventry university animal house (Coventry, U.K.).These animals received human care according 
to the guidance on the operation of animals (Scientific procedures act 1986). The investigation 
conforms to the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996).  
 
2.1.3. Krebs Henseleit buffer preparation, heart extraction and isolated heart perfusion  
The Krebs Henseleit buffer (in mM: NaCl 118.5, NaHCO3 25.0, Kcl 4.8, MgSO4 1.2, KH2PO4, 1.2, 
CaCl2 1.7, and glucose 12) was prepared freshly each day prior to each experiment, dissolved and 
gassed with 95% O2 / 5% CO2, at a pH of 7.4-7.5 at 37 °C.  
Heart Preparation 
Animals were sacrificed by cervical dislocation. The hearts were excised, placed in ice-cold buffer, 
and within 1min mounted in a constant-pressure Langendorff system (80mmHg). They were 
perfused retrogradely with a modifiedKrebs-Henseleit (KH) bicarbonate buffer containing (in mM) 
118.5 NaCl, 25 NaHCO3, 4.8 KCl, 1.2 MgSO4, 1.2 KH2PO4, 1.7 CaCl2, and 12 glucose. All 
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solutions were gassed with 95%O2-5% CO2 (pH 7.4) and maintained at 37°C. The temperature was 
permanently monitored by a thermocouple inserted in the right ventricle. A latex isovolumic 
balloon was introduced in the left ventricle through an insertion performed in the left atrial 
appendage and inflated up to 5–10 mmHg.Functional monitoring was performed via a pressure 
transducer connected to a Lab System chart recorder. Left ventricular developed pressure, heart 
rate, and coronary flow were registered at regular intervals. To induce ischemia, a surgical needle 
was inserted under the left main coronary artery and the ends of the thread were passed through a 
small plastic tube to form a snare. Tightening the snare induced regional ischemia and releasing the 
ends of the thread allowed reperfusion to commence. At the end of reperfusion, the snare was 
tightened to re-occlude the coronary artery branch. A saline solution of 0.12% Evans blue was 
infused slowly via the aorta to delineate the non ischemic zone of the myocardium, which stained 
dark blue. The hearts were frozen, sliced into 1-mm-thick transverse sections, and incubate in 
triphenyl-tetrazolium chloride solution (1% in phosphate buffer, pH 7.4) at 37°C for 10–12 min. 
They were then fixed in 10% formalin for at least 4 h. Viable tissue stained red and infarcted tissue 
appeared pale. The risk zone and infarct areas were traced onto acetate sheets. With the use of 
computerized planimetry (Summa Sketch II, Summagraphics), the percentage of infarcted tissue 
within the volume of the myocardium at risk was calculated (I/R%). 
2.1.4. Measurement of individual parameters, LVDP, HR and CF 
When the coronary perfusion was performed in the heart was working properly, a latex, fluid filled 
is volumetric balloon was inserted in the left ventricle through the left atrial appendage and inflated 
to give a preload of 8 to 10 mmH g. The balloon was connected with a pressure transducer through 
which the LVDP and HR was monitored by the help of power lab system (ADI instruments, 
Mountain View, CA). It should be maintained and make sure that the pressure transducer system 
was calibrated every time before the experiment.  




2.1.5. Treatment protocol  
The treatment protocol is shown in Figure below. All hearts were allowed to stabilise for 20 
minutes prior to the induction of regional ischemia for 35 minutes, followed by 120 minutes of 




Figure 2.1.5.a. Representation of experimental protocol for infarct studies 
 
Experimental groups 
The hearts were allocated to one of the following 10 treatment groups: 
Group 1: Control hearts; no drug was added at reperfusion. 
Group 2, 3, 4, and 5: Drugs were added at reperfusion for 120 minutes (salbutamol 1 nm, 10nm, 
100nm, ICI with salbutamol, CGP with salbutamol, ICI alone, CGP alone) 
2.1.6. Infarct size analysis 
After finishing the reperfusion, the surgical thread was pulled tightly and tied for the re-occlusion in 
the left coronary artey. Then, the saline solution of Evans blue was slowly perfused through the 
valve of the cannula in to the aorta. This saline solution stains in blue colour. After that, the hearts 
were frozen for 1-4 hrs at -20. Hearts were sliced in to 2-3 sections, and placed in freshly prepared 




  Stabilisation (20 minutes)               Ischemia (35 minutes)                          Reperfusion (120 minutes) 
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heart slices were then put in 10% formaldehyde solution for 24hrs before the observation. This step 
increased the contrast between the infarct and risk areas. Within each sliced heart section, the 
pink/red areas were identified as risk tissue and the pale white areas were identified as infarct tissue. 
 
 
                                        
 Figure 2.1.6.a. Photograph of an isolated rat heart perfused with Evans blue 
2.1.7. Infarct and risk area measurements 
The area measurement of the infarct and risk zone is a very wide procedure. The slices were placed 
between two glass plates and pressed. It was then very carefully secured with clips. An acetate sheet 
placed on the top of the plate in order to mark the risk and infarct areas according to the slice 
colours. Each of these marks were analysed by the help of computerised planimettry. (Image Tool 
version 3.1, Rockford, USA) 
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Figure 2.1.7.a. Representative photograph of an isolated rat heart slices perfused with 
Evans blue and TTC stained. The viable tissue is stained blue, risk tissue stained in 
pink and infarct tissue in pale/white. 
 
2.2 Myocyte Isolation 
2.2.1. Introduction to Myocyte Isolation 
The perfusion of the rat heart was performed in a modified langendroff system. In myocyte 
isolation, the rat heart was cannulated in a retrospective way with three different buffers. 
2.2.2. Preparation of buffers and reagents 
Krebs-Henseleit buffer was prepared with the following components (in mM); NaCl 116, KCl 5.4, 
MgSO4.7.H20 0.4, Glucose 10, Taurine 20, Pyruvate 5, Na2HPO4.12H20 0.9 dissolved in HPLC 
grade H20.  The solution was stirred and oxygenated with 95% O2/5% CO2 for 30 minutes at room 
temperature.  After 30 minutes, NaHCO3 (25mM) was added.  The solution was incubated in a 
370C water bath.  Once the desired temperature of 370C was reached (~10 minutes), the pH was 
adjusted to 7.4 with NaOH. The remaining buffers were freshly prepared. Krebs Buffer with 
addition of CaCl2 (0.75mM), Collagenase (Krebs buffer containing 0.5% bovine serum albumin 
(Roche Biochemicals) and 0.075% Collagenase (Type II) (Worthington Biochemicals)), and 
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Restoration Buffer (Krebs buffer containing 1% bovine serum albumin, 5mM Creatine, 2mM 
Carnitine, 50µM CaCl2 and 1% Penicillin-Streptomycin). 
2.2.3. Isolation of adult rat cardiomyocytes 
The hearts were quickly excised, mounted on a Langendorff apparatus, and perfused with modified 
ADS control buffer containing(in mM) 137 NaCl, 3.8 KCl, 0.49 MgCl2, 4 HEPES, 10glucose, and 
10 2,3-butanedione monoxime (pH 7.4). The perfusate was bubbled with 95% O2-5% CO2 and 
maintained at 37°C. After 5 min, the hearts were switched to a modified tyrode solution containing 
1.0 mg/ml collagenase (Worthington type II) and 50 _M calcium for 10–15 min. They were then 
perfused for 5 min with ADS buffer containing 50 M calcium alone. The hearts were removed from 
the perfusion apparatus, and the atria were trimmed away. The ventricles were minced and 
incubated in a shaking bath for 5 min in collagenase containing solution. Cells were then filtered 
through nylon mesh and washed with restoration buffer [containing (in mM) 137 NaCl, 3.8 KCl, 
0.49 MgCl2, 4 HEPES, 10 glucose, 102,3-butanedione monoxime, 2 carnitine, 5 creatine, 5 
taurine,and 5 Na-pyruvate (pH 7.4)]. The calcium concentration was gradually brought back to 1.25 
mM. 
2.2.4. Hypoxia / Reoxygenation  
The cardiac myocytes were exposed to lethal simulated ischemia as follows: the normal restoration 
medium was replaced with 2 ml Esumi ischemic buffer(5) [containing (in mM) 137 NaCl, 12 KCl, 
0.49 MgCl2, 0.9CaCl2 _H2O, 4 HEPES, 20 Na-lactate, 10 deoxyglucose, and10 KCN (pH 6.5)], 
and the cells were incubated at 37°C for 45min in the hypoxic chamber in an atmosphere of 0% O2-
5%CO2 balanced with argon (BOC gases). For control conditions with or without drug treatments, 
myocytes were cultured with 2 ml modified Esumi control buffer for 2.75 h at 37°C in an 
atmosphere of 21% O2-5% CO2 balanced with N2 (normoxicenvironment). To investigate whether 
salbutamol protected adult cardiac myocytes from reoxygenation injury, the cells were incubated 
with different concentrations of salbutamol (1μM, 0.1μM, 10nM, 1nM, 0.1nM, 0.01nM) for 2 h at 
                                                                             
35 
 
the point of reoxygenation and in the presence and absence of the selective beta antagonists CGP 
12177 and ICI-118551 
2.2.5. Flow Cytometry Analysis 
The fluorescence assimilated cell sorter (FACS, Becton Dickinson) was used for analysis of 
myocytes treated +/- drugs after hypoxia/reoxygenation and normoxic controls.  Two different 
experimental models were used. 1) Vibrant ® Apoptosis Assay Kit #10. It was used for 
measurement of live, necrotic and apoptotic cell populations. 2) Intracellular staining for Caspase-3 
using Alexa Fluor® 488 conjugate. It was used to detect cleaved Caspase-3 protein expression 
levels by Flow Cytometry Analysis 
 
 
2.2.6. Measurement of Apoptosis and Necrosis 
The cells were washed with 1 ml of cold PBS (pH 7.4; 140m M NaCl, 5m McCall, and 1.8m M 
CaCl2). They were then incubated for 10min in the dark at room temperature in annexin V-FITC 
solution (1:50 in annexin binding buffer). Propidium iodide(PI; 100 mg/ml) was added to the 
myocytes loaded with annexin V. Samples were analyzed immediately by flow cytometry using a 
Partec flow cytometer (Partec; Mu¨ nster,Germany) equipped with a 488-nm argon laser, with 
settings optimized for detection of fluoresce in and PI. Annexin V has been shown previously to 
detect the early stages of apoptosis by binding to the phosphatidyl serine (PS) residues, which are 
trans-located on the external face of the cell membrane. Translocation of PS occurs early in 
apoptosis while the cell membrane is still intact. Cellular necrosis was determined using PI. The 
assay is based on the vital binding of PI to the nuclei of cells whose plasma membranes have 
become permeable due to cell damage. Results are expressed as the percent annexin V-positive/PI-
negative (early apoptotic) and annexin-positive/PI-positive (necrotic) total numbers of cells. 
                                                                             
36 
 
2.2.7. Cell Death 
 1 x Annexin V buffer was prepared from 5x stock by diluting 4 ml 5X Annexin V (50 mM HEPES, 
700mM NaCl, 12.5 mM CaCl2, pH 7.4) with 16 ml ddH20. 50 µM C12 resazurin (component B) 
was prepared by adding l µl of 1 mM C12 resazurin stock into 19 µl ddH20. 1 µM Sytox Green stain 
(component C) was prepared by adding 5 µl of 10 µM Sytox green stain into 45µl 1X Annexin V 
buffer. 
The measurement of apoptotic myocytes were done by Annexin V allophycocyanin, which has a 
higher affinity for Sytox green dye. Apoptotic myocytes were measured using Annexin V 
allophycocyanin that has high affinity for phosphatidyl serine (PS).  
The cell suspensions from the 24 well plates were transferred to the respective labelled eppendroffs. 
Then, these eppendroffs were undergone a centrifugation at 500 rpm for 5 minutes. The supernatant 
was removed and the 300µl of annexin V buffer was added. Then, these cells were meant to be 
centrifuged at 500 rpm for 5 minutes. The supernatant was removed and add 100µl of annexin V. 
The pellets were resuspended by the addition of 1 µl component B, 1 µl component C and 5µl 
component A. After that, these eppendroffs were wrapped with a foil and placed in room 
temperature for 15 minutes. Finally, 400 µl Annexin V buffer was added and analyse on the FACS 





2.2.8. Caspase-3 Intracellular Staining 
Cells from the 24 well plates were transferred to the labelled eppendroffs.These eppendroffs were 
centrifuged at 1200 rpm for 2 minutes. After the centrifugation, the supernatant was removed and 
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cell pellets were washed with 2.5ml of phosphate buffered saline (PBS).Then, 3% formaldehyde 
was added and incubated at 370C for 10min.  After that, they were chilled in ice for 1 min. Then, it 
was centrifuged at 1200 rpm for 2 minutes. The supernatant was removed and the cells were 
permiabilised with 90%ice cold methanol, and incubated for 30 minutes. The cells were centrifuged 
at 1200 rpm for 2 min. After removing the supernatant, the cells were washed twice in 200ml 
incubation buffer (0.5% bovine serum albumin in PBS).  Cells were placed at room temperature in 
1000µl incubation buffer for 10 min. After that, the cells were incubated for 1 hour at room 
temperature in 1:100 dilution of Caspase-3 cleaved. Cells were centrifuged at 1200 rpm for 2 min 
and washed with 2X in antibody dilution buffer.  Then, the cell pellets were resuspended in 200µl 
of secondary antibody, (Alexa Fluor 488).The cells were centrifuged at 1200 rpm for 2 minutes and 














3.1 Hemodynamic data analysis 
 
The haemodynamic data consists of the measurement of left ventricular developed pressure, heart 
rate and coronary flow. Assessment of Left ventricular pressure, Heart rate, Coronary flow in the 
presence of different concentrations of β2 agonist Salbutamol has been identified that, there was no 




Figure 3.1.a. The chart shows the changes in left ventricular developed pressure in 
isolated rat heart subjected 35 minutes of ischemia and 165 minutes of reperfusion. 
Different concentrations of the β2 agonist salbutamol were administered at 
reperfusion. Results are expressed as mean of the stabilisation period. MEAN + SEM. 
n=6 





                           *p<0.05 Salbutamol 100nM vs. Ischaemia/Reperfusion. 
Figure 3.1.b.The chart shows the changes in Coronary flow in isolated rat hearts 
subjected to 35 minutes of ischaemia and 165 minutes of reperfusion. The β2 agonist 
Salbutamol was administered at reperfusion. Results are expressed as the mean of 
stabilisation period MEAN+SEM. n=6. 
 




                                          #p<0.05 Salbutamol 100nM vs. Ischaemia/Reperfusion 
Figure 3.1.c. The chart shows the changes in heart rate in isolated rat hearts subjected 
to 35 minutes of ischaemia and 165 minutes of reperfusion. The β2 agonist Salbutamol 
was administered at reperfusion. Results are expressed as mean of the stabilisation 
period MEAN+- SEM. n=6 
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3.2 Infarct Size to Risk Ratio Analysis 
 
3.2.1. Effect of β2 adrenoceptor agonist Salbutamol when administered at reperfusion in the 
rat myocardial model of ischaemia reperfusion injury. 
The main focus of this study was to investigate whether the β2 agonist Salbutamol has a toxic effect 
on the rat heart when administered throughout reperfusion. Three different concentrations (1nM, 
10nM, 100nM) of Salbutamol were used in this experiment. Isolated perfused heart underwent 35 
minutes of ischaemia and 165 minutes of reperfusion. β2 agonist Salbutamol (1nM, 10nM, 100nM) 
was administered throughout the reperfusion period. The study showed that the administration of 
β2agonist Salbutamol (100nM) throughout the reperfusion period significantly increases infarct size 
to risk ratio compared to the non-treated control groups. (P<0.001 vs. non treated controls, Fig 
3.2.1).Administration of salbutamol (1nM or 10nM,) throughout the reperfusion had no significant 
effect on infarct size to risk ratio compared to non-treated control hearts (P>0.05 vs. non-treated 
controls, Fig 3.2.1.).  
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                                              ***P<0.001 vs. Normoxia, ### P<0.001 vs. Isc/Rep  
Figure.3.2.1. Infarct size to risk ratio (%) in non-treated control and salbutamol 
treated ischaemic reperfused hearts. Isolated perfused hearts were subjected to 35 
minutes of ischaemia and 165 minutes of reperfusion where the β2 adrenoreceptor 
Salbutamol in different concentrations was administered throughout reperfusion. 
Results are shown as MEAN +/- SEM from 4-5 individual experiments. 
 
 
3.2.2. Role of β2agonist salbutamol (100nM) in the presence and absence of beta2 antagonist 
ICI-118551 when administered at the reperfusion in the rat myocardial model of ischaemia 
reperfusion injury. 
Administration of Salbutamol (100nM) throughout the reperfusion period significantly increased 
infarct size to risk ratio (%) in hearts subjected to 35 minutes of ischaemia and 165 minutes of 
reperfusion. To determine whether the cardio toxic effect of Salbutamol was due activation of β2 
adrenoceptors, we used the β2 adrenoceptors antagonist ICI.  
Administration of salbutamol in the presence of the β2 adrenoceptor antagonist ICI decreased the 
infarct size to risk ratio. Administration of ICI alone throughout reperfusion has no significant 
effect on infarct size to risk ratio (%) compared to non-treated ischaemic reperfused hearts (P>0.05 
vs. non-treated control, Fig 3.2.2.). 
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***P<0.001 vs. Normoxia  ### P<0.001 vs. Isc/Rep  $$$ P<0.001 vs. Sal 100nM 
Figure3.2.2. Infarct size to risk ratio (%) in non-treated control and salbutamol treated 
ischaemic reperfused hearts. Isolated perfused hearts were subjected to 35 minutes of 
ischaemia and 165 minutes of reperfusion where the β2 adrenoreceptor salbutamol 
(100nM) in the presence and absence of β2 antagonists ICI-118551 was administered 
throughout reperfusion. Results are shown as mean + SEM from 4-5 individual 
experiments. 
 
3.2.3. Role of β2agonist salbutamol (100nM) in the presence and absence of beta1 antagonist 
CGP-12177 when administered at the reperfusion in the rat myocardial model of ischaemia 
reperfusion injury. 
The administration of salbutamol (100nM) in the presence and absence of β1 antagonist CGP -
12177 throughout the reperfusion significantly reversed the cardio-toxic effects of salbutamol 
(P<0.001 vs. Salbutamol, Fig 3.2.3). 
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Administration of CGP-12177 alone, throughout reperfusion has no significant effect on infarct size 
to risk ratio (%), compared to non-treated ischaemic/reperfused hearts (P>0.05 vs. Isc/Rep, Fig 
3.2.3.
 
***P<0.001 vs. Normoxia ### P<0.001 vs. Isch/Rep **P<0.01 vs. Sal 100nM. 
Figure3.2.3. Infarct size to risk ratio (%) in non-treated control and salbutamol treated 
ischaemic reperfused hearts. Isolated perfused hearts were subjected to 35 minutes of 
ischaemia and 165 minutes of reperfusion where the β2 adrenoreceptor Salbutamol 
(100nM) in the presence and absence of β1 antagonists CGP 12177 was administered 
throughout reperfusion. Results are shown as mean + SEM from 4-5 individual 
experiments. 
3.2.4. Role of β2agonist salbutamol (100nM) in the presence and absence of β1 antagonist 
CGP-12177 and β2 antagonist ICI-118551 when administered at the reperfusion in the rat 
myocardial model of ischaemia reperfusion injury. 
To determine whether the cardio toxicity afforded by salbutamol (100nM), we administered 
salbutamol in the presence and absence of β1 antagonist CGP and β2 antagonist ICI.  
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The administration of salbutamol (100nM) in the presence of the β1 antagonist CGP-12177 and 
beta2 antagonist ICI significantly reversed the cardio toxic effect of Salbutamol in isolated perfused 
rat hearts subjected to 35 minutes of ischaemia and 165 minutes of reperfusion (P<0.001 vs. 
Salbutamol, Fig 3.2.4).  
 
***P<0.001 vs. Normoxia ### P<0.001 vs. Isch/Rep $$$ P<0.001 vs. Sal 100nM 
Figure.3.2.4. Infarct size to risk ratio (%) in non-treated control and salbutamol 
treated ischaemic reperfused hearts. Isolated perfused hearts were subjected to 35 
minutes of ischaemia and 165 minutes of reperfusion where the β2 adrenoreceptor 
Salbutamol (100nM) in the presence and absence of β1 antagonists CGP 12177 and β2 
antagonist ICI 118551 were administered throughout reperfusion. Results are shown as 
mean + SEM from 4-5 individual experiments. 
 
3.3 Role of β2 agonist salbutamol in the live cell population of rat cardio myocytes 
administered at reperfusion in the isolated perfused heart.  
The β2 agonist salbutamol at different concentrations was administered throughout the 
reoxygenation period. After reoxygenation the cells were stained with Fluorochromes specific for 
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apoptotic, necrotic and live cells and analysed on the flow cytometer.Isolated rat cardiomyocytes 
subjected to 6 hours of hypoxia followed by 18 hours of reoxygenation resulted in significant 
decrease in the number of live cells when compared to normoxic group (P<0.001 vs. Normoxia, Fig 
3.3.0). 
To find out the effect of the β2 agonist salbutamol, rat cardiomyocytes were subjected to 6 hours of 
hypoxia followed by 18 hours of reoxygenation. β2 agonist Salbutamol (1μM, 0.01μM, 10nM, 
1nM, 0.01nM) was administered throughout the reoxygenation period.  
Administration of Salbutamol (1μM, 0.1μM, 1nM, 0.1nM) throughout reoxygenation significantly 













*P<0.05 vs. Hyp/Reox, ***p<0.01 vs. Normoxia 
Figure.3.3.0. Assessment of live cells in isolated adult rat cardiomyocytes subjected to 6 
hours hypoxia and 18 hours of reoxygenation. The β2 agonists salbutamol (1μM, 
0.1μM, 10nM, 1nM, 0.1nM, 0.01nM) were added at the onset of reoxygenation. Results 
are shown as Mean+SEM n=6-8 experiments.  
 
3.3.1. Role of β2 agonist salbutamol in the live cell population of rat cardiomyocytes in the 
presence and absence of β2 antagonist IC1-118551 when administered throughout 
reoxygenation  
Administration of β2 agonist salbutamol in rat cardiomyocytes in the presence and absence of β2 
antagonist ICI was performed to find out whether the presence of β2 antagonist can significantly 
reverse the cardio-toxic effects of salbutamol. 
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Isolated rat cardiomyocytes were subjected to 6 hours of hypoxia followed by 18 hours of 
reoxygenation. The β2 agonist Salbutamol (1nM, 0,01nM) was administered throughout the 
reoxygenation period in the presence of the β2 antagonist ICI. 
The administration of β2 agonist Salbutamol (1nM) in the presence of β2 antagonist ICI in rat 
cardiomyocytes throughout reoxygenation was failed to reverse the cardio toxic effect of 
salbutamol (P>0.05 vs. Salbutamol, Fig 3.3.1). Administration of Salbutamol (0.01nM) in the 
presence of β2 antagonist ICI was significantly abolished the cardio toxicity. 
Administration of ICI alone throughout reoxygenation had no significant effect on live cell 
population compared to non-treated cells, subjected to hypoxia/reoxygenation injury (P>0.05 vs. 
Hyp/Reox, Fig 3.2.1) 
 *p<0.01 vs. Hypo/Reox, ***p<0.001 vs. Normoxia, #p<0.05 vs. Salbutamol 0.01nM. 
Figure.3.3.1. Assessment of live cells in isolated adult rat cardiomyocytes subjected to 6 
hours hypoxia and 18 hours of reoxygenation. The β2 agonist salbutamol (1nM, 
0.01nM) was added in the presence and absence of β2 antagonist ICI-118557 at the 
onset of reoxygenation. Results are shown as Mean+ SEM. 




3.3.2. Role of β2 agonist salbutamol in the live cell population of rat cardiomyocytes in the 
presence and absence of β1 antagonist CGP-12177 when administered at reperfusion in 
isolated perfused heart. 
The β2 agonist salbutamol (1nM, 0.01nM) was administered in the presence and absence of β1 
antagonist CGP throughout the reoxygenation period. Administration of salbutamol (1nM or 
0.01nM) significantly reduced the population of live cells compared to non-treated control cells 
(P<0.001 vs. Hyp/Reox, Fig 3.3.2.).  Co-administration of salbutamol (1nM) in the presence of the 
β1 antagonist CGP significantly reversed the decrease in live cells when Salbutamol (1nM) was 
administered alone throughout reoxygenation.    
 
                     ***p<0.001 vs. Normoxia,*p<0.05 vs. Hypo/Reox. #p<0.05 vs. Sal 1nM 
Figure.3.3.2. Assessment of live cells in isolated adult rat cardiomyocytes subjected to 6 
hours hypoxia and 18 hours of reoxygenation. The β2 agonist Salbutamol (1nM, 
0.01nM) was added in the presence and absence of β1 antagonist CGP-12177 at the 
onset of reoxygenation. Results are shown as Mean+ SEM. 
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3.4 The effect of the β2 agonist Salbutamol necrotic cell death in rat cardiomyocytes 
subjected to hypoxia / reoxygenation injury. 
The percentage of the necrotic cells was significantly increased when the β2 agonist salbutamol 
(0.1µM, 0.1nM, 0.01nM) was administered throughout the reperfusion when it was  compared to 
non-treated cells subjected to 6 hours of hypoxia and 18 hours of reoxygenation (P<0.05 vs. 
Hyp/Reox,  Figure 3.4.0.).  
 
                             ***p<0.05 vs. Normoxia, #p<0.05 vs.  Hypo/Reox. 
Figure.3.4.0. Assessment of necrotic cells in isolated adult rat cardiomyocytes subjected 
to 6 hours hypoxia and 18 hours of reoxygenation. The β2 agonist salbutamol (1μM, 
0.01μM, 10nM, 1nM, 0.1nM, 0.01nM) was added at the onset of reoxygenation. Results 
are shown as Mean+SEM 
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3.4.1. Role of β2 agonist salbutamol (1nm,and 0.01nm) when administered in the presence and 
absence of β2 antagonist ICI-118551 in necrotic cells of adult rat cardiomyocytes subjected to 
6h hypoxia and 18h reoxygenation. 
 Administration of salbutamol (0.01nM) throughout reoxygenation resulted in a significant increase 
in necrotic cardiomyocytes (P<0.05 vs. Hyp/Reox, Fig 3.4.1). Administration of salbutamol in the 
presence of the β2 AR antagonist ICI reversed the pro-necrotic effect of salbutamol, but did not 
reach statistical significance (Fig 3.4.1). Administration of ICI alone throughout reoxygenation had 
no significant effect of cardiac myocyte necrosis (Fig 3.4.1.). 
 
***p<0.001 vs. Normoxia. #p<0.05 vs. Hypo/Reox. 
Figure 3.4.1. Assessment of necrotic cells in isolated adult rat cardiomyocytes subjected 
to 6 hours hypoxia and 18 hours of reoxygenation. The β2 agonist salbutamol (1μM, 
0.01nM) was added in the presence and absence of β2 antagonist ICI-118551 at the 
onset of reoxygenation. Results are shown as Mean+ SEM. 
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3.4.2. Assessment of the administration of β2 agonist salbutamol (1nM, 0.01nM) in the 
presence and absence of β1 antagonist CGP-12177 in necrotic cells of adult rat 
cardiomyocytes subjected to 6h hypoxia and 18h reoxygenation. 
Administration of Salbutamol (0.01nM) throughout reoxygenation resulted in a significant increase 
in necrotic cardiomyocytes (P<0.05 vs. Hyp/Reox, Fig 3.4.2). Administration of salbutamol in the 
presence of the β1 AR antagonist CGP failed to reverse the pro-necrotic effect of salbutamol.  
Administration of CGP alone throughout reoxygenation had no significant effect of cardiac 
myocyte necrosis (Fig 3.4.2.). 
                                     
***p<0.001 vs. Normoxia. **p<0.05 vs. Hypo/Reox 
Figure.3.4.2. Assessment of necrotic cells in isolated adult rat cardiomyocytes subjected 
to 6 hours hypoxia and 18 hours of reoxygenation. The β2 agonist salbutamol (1μM, 
0.01nm) was added in the presence and absence of β2 antagonist CGP-12177 at the 
onset of reoxygenation. Results are shown as Mean+ SEM. 
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3.5 Role of β2 agonist salbutamol in the apoptotic cell population of rat cardio myocytes 
when administered at reperfusion  
Rat cardiac myocytes subjected to 6 hours of hypoxia and 18 hours of reoxygenation resulted in a 
significant increase in apoptosis compared to naive non-stressed cardiac myocytes (P<0.001 vs. 
Normoxia, Fig 3.5.0).Administration of salbutamol ((1μM-0.01nM) had no significant effect on 
cardiac myocyte apoptosis compared to non-stressed cardiac myocyte.(P>.5 vs. Normoxia Fig 
3.5.0) 
 
                                         ***p<0.01 vs. Normoxia 
Figure 3.5.0. Assessment of apoptotic cells in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The β2 agonist salbutamol 
(1μM, 0.01nM) was added at the onset of reoxygenation. Results are shown as 
Mean+SEM. 
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3.5.1.  Role of β2 agonist salbutamol (1nM,and 0.01nM) when administered in the presence 
and absence of β2 antagonist ICI-118551 in apoptotic cells of adult rat cardiomyocytes 
subjected to 6h hypoxia and 18h reoxygenation. 
Isolated cells were exposed to 6 hours of hypoxia and 18 hours of reoxygenation in the presence of 
β2 agonist salbutamol in the presence and absence of β2 antagonist ICI.  Administration of 
Salbutamol in the presence of the β2 adrenoceptor antagonist increased cell death by apoptosis but 
did not reach statistical significance (Fig 3.5.1.). 
Administration of ICI alone throughout reoxygenation also increased the cardiac myocyte death by 
apoptosis, but failed to reach statistical significance (Fig 3.5.1.). 
 
***p<0.05 vs. Normoxia 
Figure.3.5.1. Assessment of apoptotic cells in isolated adult rat cardiomyocytes subjected to 6 
hours hypoxia and 18 hours of reoxygenation. The β2 agonist salbutamol (1μM, 0.01nM) was 
added in the presence and absence of β2 antagonist IC-118551 at the onset of reoxygenation. 
Results are shown as Mean+ SEM. 
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3.5.2.  Role of β2 agonist salbutamol (1nM,and 0.01nM) when administered in the presence 
and absence of β1 antagonist CGP-12177 in apoptotic cells of adult rat cardiomyocytes 
subjected to 6h hypoxia and 18h reoxygenation. 
 
The β2 adrenoceptor agonist salbutamol was administered in the presence and absence of β1 
adrenoceptor blocker CGP in adult rat cardiomyocytes subjected to hypoxia/reoxygenation injury. 
Administration of Salbutamol (1nM, 0.01nM) throughout reoxygenation had no significant effect of 
cardiac myocyte apoptosis compared to non-treated cardiac myocytes subjected to 
hypoxia/reoxygenation injury.  
Administration of the β1 antagonist CGP alone throughout reoxygenation had no significant effect 
of cardiac myocyte apoptosis (Fig 3.5.2.). 
 
***p<0.05 vs. Normoxia 
Figure.3.5.2. Assessment of apoptotic cells in isolated adult rat cardiomyocytes subjected to 6 
hours hypoxia and 18 hours of reoxygenation. The β2 agonist salbutamol (1μM, 0.01nM) was 
added in the presence and absence of β1 antagonist CGP-12177 at the onset of reoxygenation. 
Results are shown as Mean+ SEM. 




3.6 Intracellular Caspase-3 levels in cardiomyocytes as analysed by flowcytometry after 
the administration of salbutamol at reoxygenation.  
Caspase-3 protein has a pivotal role in the execution phase of apoptosis. The β2 adrenoceptor 
agonist salbutamol was administered throughout reoxygenation in isolated adult rat cardiac 
myocytes subjected to 6 hours of hypoxia and 18 hours of reoxygenation.   
Cardiac myocytes subjected to 6 hours of hypoxia and 18 hours of reoxygenation resulted in a 
significant increase in cleaved caspase 3 activity (P<0.01 vs. Normoxia, Fig 3.6.0). 
Administration of salbutamol(1μM, 10nM, and 0.1nM) throughout reoxygenation  significantly 
increased cleaved caspase-3 activity in isolated adult rat cardiac myocytes subjected to 6 hours of 
hypoxia and 18 hours of reoxygenation compared to non-treated Hyp/Reo group (P<0.05 vs. 
Hyp/Reox,Figure.3.6.0.). 
 
    ***p<0.01 vs. Normoxia. #p<0.05 vs. Hypo/Reox. 
Figure.3.6.0. Cleaved-caspase3 activity in isolated adult rat cardiomyocytes subjected 
to 6 hours of hypoxia followed by 18 hours of reoxygenation. The β2 agonist salbutamol 
(1μM, 0.01μM, 1nM, 0.1nM, 0.1pM, 0.01pM, 10nM.0.01nM) was administered at the 
onset of reoxygenation. Mean + SEM of 5 individual experiments.  




 3.6.1. Intracellular caspase-3 levels in the cardiomyocytes after the administration of 
salbutamol (1nM, 0.01nM) in the presence and absence of β2 antagonist ICI-118551 along at 
reoxygenation. 
To determine whether the β2 antagonist ICI make any impact on the caspase3 activity in the 
presence of salbutamol (1nM and 0.1nM), salbutamol was administered with the presence and 
absence of the β2 antagonist ICI in the isolated rat cardiomyocytes. 
Administration of salbutamol (1nM and 0.1nM) alone increased caspase 3 activity in the isolated 
adult rat cardiomyocytes at the onset of reperfusion, subjected to 6 hours of hypoxia and 18 hours 
of reoxygenation. 
Administration of salbutamol (1nM,0.1nM)  throughout the reperfusion in the presence of β2 
antagonist ICI showed no significant effect compared to non-treated cardiac myocytes (P>0.05 vs. 
Hyp/Reox, Figure3.6.1.). Administration of ICI throughout reoxygenation alone had no significant 










#p<0.05 Salbutamol (1nM) vs. Hypo/Reox.***p<0.001 vs.Normoxia 
Figure.3.6.1. Cleaved-caspase 3 activity in isolated adult rat cardiac myocytes 
subjected to 6 hours of hypoxia followed by 18 hours of reoxygenation. The β2 agonist 
salbutamol (1nM, 0.1nM) was administered in the presence and absence of β2 






3.6.2. Intracellular caspase3 levels in cardiomyocytes as analysed flowcytometry after the 
administration of salbutamol (1nM, 0.1nM) in the presence and absence of β1 antagonist 
CGP-12177 at the onset of reoxygenation. 
Administration of salbutamol (1nM) caused a significant increase in caspase 3 activity compared to 
non-treated cardiac myocytes (P<0.05 vs. Hyp/Reox, Fig 3.6.2.).  This increase in caspase 3 activity 
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was not reversed in the presence of the β1 adrenoceptor antagonist CGP P>0.05, Fig 3.6.2.). 
Administration of CGP alone throughout reoxygenation had no significant effect on caspase 3 
activity compared to non-treated cardiac myocytes (P>0.05, Fig 3.6.2).  
 
                                               ***p<0.05 vs. Normoxia, #p<0.05 vs.Hyp/Reox. 
Figure.3.6.2. Cleaved-caspase 3 activity in isolated adult rat cardiac myocytes 
subjected to 6 hours of hypoxia followed by 18 hours of reoxygenation. The β2 agonist 
salbutamol (1nM, 0.1nM) was administered in the presence and absence of β1 












4. GENERAL DISCUSSION 
Ischemic heart disease is the most important factor in the progression of myocardial infarction in 
the world today. Many studies have tried to identify the major factors to reduce the burden of 4. 
General discussion 
ischemic heart disease related events in human. For reducing the post ischaemic infarct size, 
patients undergo treatments like thrombolysis, percutaneous angioplasty, and primary bypass 
surgery.  There remains an unscored need for novel therapies and strategies to ameliorate to 
detrimental effects of ischaemic heart disease and myocardial infarction.  
It is unclear that whether the use of β2 agonists makes an increase risk of heart failiure.β2 agonists 
are often used in the short term treatment of enhancement of heart contractility due to its improving 
cardiac performances in patients. But, the data from the Acute decompensate heart failure national 
registry emergency module showed that 14% of the people presently with dysponea are treated 
from COPD. The use of inhaled β2 agonist in these heart failure patients will make COPD 
associated with a worse outecome.They also suggested that the mortality rate is also very high in 
these patients who received the β2 agonists (Maria et al., 2009). 
 
The recent discovery by Vinten-Johnsen et al. of ischaemic post conditioning made a huge impact 
on appealing the pharmacological interventions to be applied at the onset of reperfusion.There are 
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mainly two types of treatments of ischaemic heart diseases conventional and alternative treatments. 
Conventional treatment is one which includes the treatment by the usage of drugs. 
Cardio toxicity is a well-known side effect of several drugs which ultimately cause the long term 
morbidity. These cytotoxic drugs involve in the formation of free radicals and cause the oxidative 
stress. This leads to apoptosis of cardiac myocytes (Schimmel et al., 2004). The standard method 
for identifying the cardio-toxic compounds involves the histopathilogical analysis of tissue section 
(Brad et al., 2008). A large number of studies have shown endogenenous and exogenous agents to 
arbitrate ischaemia reperfusion injury. Some of them having cardio-toxic effects and others having 
cardio-protective abilities (Hausenloy and Yellon.2004). 
The aim of this study was to investigate the cardio toxicity of the beta 2 adrenoceptor agonist 
salbutamol in the isolated perfused rat heart model of ischaemia reperfusion injury and the adult rat 
cardiac myocyte model of hypoxia/reoxygenation injury. Previous studies have proven that the beta 
agonist salbutamol will make severe problems in the heart. Barilan et al., 2010 has done a recent 
study on asthma patients who were using salbutamol .The result of that study was the usage of 
salbutamol will finally ends with myocardial infarction. In the present study, salbutamol was 
administered at the time of reperfusion in the infarct heart model and isolated cardiomyocytes. 
Some studies have implicated the activation of salbutamol on coronary circulation. George et.al., 
(2006) discussed about the effect of salbutamol on coronary circulation. George and his colleagues 
revealed a fact that the high dose of salbutamol will increase the coronary flow but not in 
proportion to the myocardium and decrease coronary flow reserve and they showed that this will 
cause many consequences in patients with coronary artery diseases causing or worsening 
myocardial infarction. In this present study the administration of salbutamol 100nM, throughout the 
reperfusion of cardiomyocytes gives a significant increase in the coronary flow compared to 
isch/rep. These findings cardiotoxicity of salbutamol were supported by the findings of George et 
al., (2006). Kochiadakis et al., (2007) researchers have shown the tolerability and safety of 
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salbutamol in COPD patients. Bernd et al., (2006) suggested that the large dose of salbutamol in 
patients with chronic obstructive pulmonary diseases will cause a comparable tolerability than other 
beta agonists such as formoterol. Besides, a study has done by Wijesinghe and his colleagues in 
2008 have made a significant research in the study of long acting beta agonists in asthma mortality. 
They have suggested that the regular use of beta agonists may have the chance to make increase in 
asthma mortality. 
Some previous studies implicated significant results in the effect of beta adrenoceptors in the heart 
during ischaemia/reperfusion.  Jatin et al., (2004) showed the adverse effects of beta agonists in 
heart during ischaemia. They have suggested that while the administration of beta agonists in high 
doses may cause cardio toxic effects by increase in the apoptotic and necrotic cell populations. 
Moreover, the studies done by Heather et al., (1999) showed some effective results with the use of 
beta agonist in heart during ischaemia. They have also concluded with the adverse effects of the use 
of beta agonists in the heart. In this present study, the administration of salbutamol on 
cardiomyocytes at reperfusion significantly increased the infarct size. The results indicate the 
cardio-toxic effect of salbutamol in heart. Especially, when salbutamol 100nM was administered 
throughout the reperfusion significantly revealed the cardio toxicity of the drug. Moreover, the beta 
antagonists ICI and CGP were administered along with salbutamol 100nM at the onset of 
reperfusion. Although the administration of the beta antagonists ICI and CGP abrogated the toxicity 
afforded by the salbutamol, these were not much significant to the control. The coordination of beta 
antagonists ICI and CGP with salbutamol 100nm administered at reperfusion was significantly 
decreased the infarct size compared to the salbutamol 100nm alone. These results are in accordance 
with the finding of Donald et al., (1999) who showed the cardio toxicity caused by the regular use 
of Salbutamol. Klaus et al., (2003) has done a study on the role of β2 adrenoceptors in the rat 
cardiomyocytes. They have found out the cardio toxic effect of beta2 agonists, and showed the 
effect of beta antagonists ICI and CGP, which resulted that these antagonists also induced the 
apoptosis and necrosis in rat cardiomyocytes. Also, this present study supported by the findings of 
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studies conducted by Ruth et al., (2000).They showed the effects of beta antagonists in cardiac 
ischaemic patients. They were suggesting the significant reduction of cardiac death in patients with 
contractile symptoms.  
The present study suggested the cardio toxicity of salbutamol, when administered in 
cardiomyocytes throughout the reperfusion. Previous studies have shown the consequences of 
salbutamol in heart. Administration of salbutamol in isolated cardiomyocytes induces a number of 
cardio-toxic properties which includes the significant decrease in the population of live cells, 
apoptosis, and necrosis. Carley et al., (2007) has been showed that it is very hard to explain the 
cardiac benefits of β2 agonist treatment in the heart failiure.In this present study the administration 
of β2 agonist salbutamol in isolated rat cardiomyocytes throughout the reperfusion significantly 
decrease the live cell population and proved its cardio-toxic effect. The Previous research has 
shown the properties of beta antagonists in the ischaemic heart diseases. Salbutamol was 
administered along with the beta antagonists ICI and CGP caused a cardio-toxic effect on the 
cardiomyocytes by decreasing the live cells of cardiomyocytes. Although, the administration of beta 
antagonists ICI and CGP   along with salbutamol (0.1nM and 1nM respectively) abrogated the 
toxicity caused by salbutamol alone, these were not significantly increase the live cells compared to 
non hypoxia group. This concept of this study is supported by the findings of Jenne (1998) and 
Carbol (2001).They showed the positive effects of beta antagonists with salbutamol. 
In this study, flow cytometry analysis of isolated myocytes subjected to hypoxia/reoxygenation 
demonstrated that there was a significant increase in the apoptotic cell population when compared 
to normoxic controls. In order to elucidate the mechanisms by which the toxic effect were observed 
there was a comparison put together on the apoptotic effect of salbutamol in coordination with the 
beta  antagonists ICI and CGP. The administration of beta antagonists ICI and CGP along with 
salbutamol (0.1nM, 1nM) at the onset of reperfusion also showed the cardio toxicity of salbutamol. 
More importantly, the administration of β2 antagonists ICI with salbutamol (0.1nM) abrogated the 
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toxicity afforded by salbutamol (1nM) and ICI alone. Besides the administration of β1 antagonist 
CGP when administered along with salbutamol showed the cardio-toxic effect by increasing the 
apoptotic cell population. These findings of this present study was supported by the findings of 
Milton parker (2003) who has done clinical studies on beta agonists activity on hearts and he 
suggested that the survival in heart failure by β blocker is not likely to related in the magnitude or 
duration of β blockade produced by the agonists. 
The study by Maak et al., (2008) in beta agonist’s activity in heart failure showed a list of adverse 
effect in the treatment. In accordance with those findings Cates et al., (2009) found that the regular 
treatment with salbutamol in chronic asthma will cause serious adverse effects in heart. The present 
study revealed the cardio toxicity of the beta agonist salbutamol by increasing the necrotic cell 
population, when salbutamol administered in cardiomyocytes throughout reperfusion. The 
administration of salbutamol (1nM) with the beta antagonist ICI and CGP also didn’t make any 
alteration in the toxicity afforded by the administration of salbutamol alone. 
Aihua et al (2006) have done a study on the role of β2 adrenoceptors in the heart following 
ischaemia/reperfusion. They have suggested that the Capase 3 activity in the cardiomyocytes 
induced apoptosis the cleaved caspase3 activity with the beta agonist salbutamol has been discussed 
in this present study. The increase in the caspase 3 level in the administration of different doses of 
salbutamol proved the cardio toxic effect of the beta agonists. Moreover, the administration of beta 
antagonist ICI and CGP has not made any abrogation in the toxicity afforded by salbutamol. These 
findings were supported by the concept of Vandenabeele et al., (2006) who found the progression in 
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5. CONCLUSION AND FUTURE DIRECTION 
To conclude, this present study novel demonstrating that the activation of β2 agonist salbutamol at 
reperfusion did not protect the ischaemic reperfused rat heart. In the langendroff model, the 
activation of salbutamol (1nM, 10nM) didn’t show any significant effect on the isolated perfused 
hearts on the onset of reperfusion. But, the administration of salbutamol (100nM) in the isolated rat 
cardiomyocytes of langendroff model significantly decrease the heart rate compared to the isch/rep. 
The cardio toxic effect of the beta agonist salbutamol was first showed by this study with 
langendroff model. 
In isolated perfused heart, by increasing the infarct size at the reperfusion the β2 agonist salbutamol 
showed the cardio toxicity of the drug. Administration of salbutamol (1nm, 10nm, 100nm) 
throughout the reperfusion significantly increased the infarct size. To determine whether this 
cardio-toxic effect of beta agonist was abolished by the beta antagonists, ICI118557, and 
CGP12177 was administered along with salbutamol 100nm on isolated perfused rat 
cardiomyocytes. This study also showed the cardio-toxic effect in isolated rat cardiomyocytes. 
However, the administration ICI and CGP alone at the onset of reperfusion was significantly 
decreased the infarct size compare to the isch/rep group. Administration of salbutamol in isolated 
rat cardiac myocytes 30 minutes after the onset of reperfusion significantly increased the cleaved 
caspase3 activity. The coordination of beta antagonists ICI and CGP with salbutamol was also 
significantly increased the cleaved capase3 activity in the cardiac myocyte model of 
hypoxia/reoxygenation. As a final point, the increase in the Isc/Rep injury by the administration of 
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The present study was carried out in an in vitro model. Further studies are required in whole animal 
in vivo model. Besides, the administration of salbutamol (100nM) along with the presence of beta 
antagonists ICI and CGP showed a significant decrease in the infarct size to risk ratio.  Therefore, 
further studies are required to briefly explain whether t higher concentrations of salbutamol with the 
beta antagonists can block the toxicity. Furthermore, the administration of salbutamol (0.1nM) with 
the beta antagonist ICI at the onset of reperfusion abolished the cardio-toxicity by increasing the 
live cell population further studies are required to determine whether cardio protective agents can 
block the toxicity. Also, the administration of salbutamol (1nM) with the beta antagonist CGP 
reversed the decrease in the live cell population when administered throughout the reperfusion. 
Therefore, further studies are required to find out whether the higher concentration of salbutamol 
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